Emory University School of Medicine
Dr. Kono’s research focus has been on the role of the fibroblast growth factor (FGF) pathway in tumor development and drug resistance to EGFR tyrosine kinase inhibitors in malignancies of the aerodigestive tract (head, neck, and lung). The goal of such research is to optimally develop the use of FGF-targeted therapies in the treatment of these malignancies, as well as identify clinically meaningful biomarkers that may predict sensitivity to such therapy.
Dr. Kono’s research interests include the development of clinical trial protocols for patients with malignancies of the head, neck, and lung. His interests include the prevention of cancer development using natural compounds (i.e. chemoprevention) in head/neck cancer, as well as developing new therapies for cancers of the head, neck, and lung. Within the clinical trials, Dr. Kono is interested in bridging discoveries in basic science with clinically relevant biomarkers.
View publications on PubMed